6.4205.45% ( -0.370 )
Delay Closed: Nov 16, 16:08:11Overview
ABBISKO-B (2256)
Abbisko Medicine Co., Ltd., together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and...
- Open
- 6.700
- High
- 6.925
- Low
- 6.310
- Prev. Close
- 6.790
- Volume
- 1.66M
- Turnover
- 10.61M
- Avg Price
- 6.405
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 9.06%
- 52wk High
- 15.000
- Volume Ratio
- 1.46
- Turnover Ratio
- 0.23%
- 52wk Low
- 6.035
- HK Mkt Cap
- 4.60B
- Market CapHKD
- 4.60B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.750
- EPSDynamic
- -0.622
- EPSStatic
- --
- BVPS
- 3.51
- P/B
- 1.83
- HK Shares
- 716.08M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 716.08M
- Min lot size
- 1,000
- Currency
- HKD
ABBISKO-B Analyst Rating
View moreForecast & Rating
Nov 12, 2026Price forecast
HK$19.39201.95%
Forecast & RatingStrong buy
9analysts
- Strong buy88.89%
- Buy11.11%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 8
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
News
Simplywall · Insider Buys Additional CN¥967k In Abbisko Medicine Stock
Market Movers · Abbisko falls 6% in Hong Kong trading
Market Movers · Abbisko climbs 6% as FDA approves pimicotinib
PUBT · Abbisko Medicine CEO Xu Yao-Chang Raises Stake to 11.26%
PR Newswire · PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT
